GlassScriptPhysician profile
Allie C Redding
NPI 1427686047
$1,003.67
in general payments reported to CMS, 2019-2025
25 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $267 · 2024: $374 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $169.97 | 2023-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.62 | 2023-2025 | Xifaxan, Trulance |
| Amgen INC. | $71.88 | 2023 | Repatha, Prolia, Evenity |
| Lilly USA, LLC | $66.56 | 2024 | Jardiance, Mounjaro, Zepbound |
| Stryker Corporation | $62.36 | 2025 | Clottriever Bold Catheter |
| Pfizer INC. | $45.66 | 2023-2024 | |
| Seqirus USA INC | $44.02 | 2024 | Fluad, Flucelvax |
| Globus Medical, INC. | $40.92 | 2025 | Senza |
| Glaxosmithkline, LLC. | $40.52 | 2023 | Shingrix, Arexvy |
| Abbvie INC. | $32.20 | 2023-2024 | |
| Esperion Therapeutics, INC. | $30.74 | 2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.14 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $28.68 | 2024 | Rexulti |
| Exact Sciences Corporation | $24.97 | 2025 | The Cologuard Plus Collection Kit |
| Organon LLC | $24.87 | 2025 | Nexplanon |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $23.17 | 2025 | Gemtesa |
| Lundbeck LLC | $21.22 | 2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $20.70 | 2023 | |
| Acadia Pharmaceuticals INC | $19.80 | 2025 | Nuplazid |
| Edwards Lifesciences Corporation | $17.78 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $17.19 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.67 | 2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $13.30 | 2024 | Voquezna |
| Cvrx, INC. | $12.93 | 2025 | Barostim Neo System |
| Medtronic, INC. | $12.80 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allie Redding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.